IRIS PubliCatt

Pera, Maria Carmela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.819
EU - Europa 1.472
AS - Asia 506
SA - Sud America 21
AF - Africa 19
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 3.840
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.795
IT - Italia 420
SE - Svezia 373
IE - Irlanda 204
SG - Singapore 152
CN - Cina 97
ID - Indonesia 97
DE - Germania 86
FR - Francia 77
RU - Federazione Russa 70
IN - India 59
GB - Regno Unito 44
FI - Finlandia 31
CZ - Repubblica Ceca 21
UA - Ucraina 19
ES - Italia 18
TR - Turchia 18
IR - Iran 17
BE - Belgio 14
IL - Israele 14
NL - Olanda 14
RO - Romania 13
MK - Macedonia 12
CH - Svizzera 11
HK - Hong Kong 11
CA - Canada 10
CI - Costa d'Avorio 10
JP - Giappone 10
PA - Panama 10
BR - Brasile 9
RS - Serbia 9
PT - Portogallo 8
KR - Corea 7
EG - Egitto 6
CO - Colombia 5
HR - Croazia 5
AR - Argentina 4
PL - Polonia 4
SK - Slovacchia (Repubblica Slovacca) 4
AT - Austria 3
BD - Bangladesh 3
DK - Danimarca 3
MX - Messico 3
PH - Filippine 3
AE - Emirati Arabi Uniti 2
BT - Bhutan 2
GR - Grecia 2
KZ - Kazakistan 2
LU - Lussemburgo 2
PK - Pakistan 2
TW - Taiwan 2
VN - Vietnam 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AU - Australia 1
BG - Bulgaria 1
CL - Cile 1
GL - Groenlandia 1
HU - Ungheria 1
LK - Sri Lanka 1
MT - Malta 1
MY - Malesia 1
OM - Oman 1
PE - Perù 1
QA - Qatar 1
SA - Arabia Saudita 1
SC - Seychelles 1
SI - Slovenia 1
TH - Thailandia 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 3.840
Salva come PNG Salva come JPEG
Città #
Chandler 460
Ashburn 299
Dublin 185
New York 131
Rome 109
Singapore 103
Jakarta 97
Milan 76
Marseille 44
Moscow 42
Boston 38
San Mateo 38
Los Angeles 36
Princeton 36
Pune 33
Chicago 32
Ann Arbor 21
Helsinki 20
Dearborn 19
Wilmington 19
Nanjing 18
Bremen 17
Palermo 17
Brno 16
Boardman 12
Seattle 12
Cattolica 11
Jacksonville 11
Redwood City 11
Abidjan 10
Andover 10
Brussels 10
Houston 10
Munich 10
Skopje 10
Kish 9
London 9
Augusta 8
Edinburgh 8
Fairfield 8
Paris 8
Turin 8
Washington 8
Amsterdam 7
Bari 7
Lancaster 7
Madrid 7
Redmond 7
Toronto 7
Busto Arsizio 6
Hong Kong 6
Jiaxing 6
Menlo Park 6
Niš 6
Seoul 6
Shanghai 6
Shenyang 6
Beijing 5
Cairo 5
Frankfurt am Main 5
Hebei 5
Hyderabad 5
Lawrence 5
Leawood 5
Lisbon 5
Mountain View 5
Norwalk 5
São Paulo 5
Zagreb 5
Barcelona 4
Bitonto 4
Bologna 4
Cambridge 4
Changsha 4
Florence 4
Fort Worth 4
Genoa 4
Giugliano in Campania 4
Jinan 4
Monza 4
Naaldwijk 4
San Francisco 4
Secaucus 4
Viterbo 4
Bern 3
Bucaramanga 3
Caorle 3
Chieti 3
Dhaka 3
Florida 3
Grottaferrata 3
Hangzhou 3
Izmir 3
Krakow 3
Kunming 3
Lappeenranta 3
Nanchang 3
Neded 3
Nuremberg 3
Ronciglione 3
Totale 2.347
Salva come PNG Salva come JPEG
Nome #
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 109
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standars of Care? 98
Revised upper limb module for spinal muscular atrophy: Development of a new module 97
Predominant distal muscle involvement in spinal muscular atrophy 83
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 80
Developmental milestones in type I spinal muscular atrophy 78
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 77
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 76
Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study 72
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 71
Developmental milestones in type I spinal muscular atrophy 68
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 68
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 65
Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? 65
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 65
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 64
MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients 64
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 64
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 64
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 59
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 59
Assessing floppy infants: a new module 58
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 57
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 57
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 56
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 55
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. 54
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 52
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 52
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 52
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 50
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 50
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 49
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 49
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 48
Clinical Variability in Spinal Muscular Atrophy Type III. 48
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 47
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 47
Development of an academic disease registry for spinal muscular atrophy 46
Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019 43
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 42
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 41
1st Italian SMA Family Association Consensus Meeting: Management and recommendations for respiratory involvement in spinal muscular atrophy (SMA) types I-III, Rome, Italy, 30-31 January 2015 41
Gain and loss of abilities in type II SMA: A 12-month natural history study 41
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment 40
Revised upper limb module for spinal muscular atrophy: 12 month changes 40
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 39
Age and baseline values predict 12 and 24-month functional changes in type 2 SMA 38
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 37
Risdiplam in Type 1 Spinal Muscular Atrophy 37
Revised upper limb module for spinal muscular atrophy: Development of a new module 37
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 37
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 36
Spinal muscular atrophy — insights and challenges in the treatment era 36
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 35
Longitudinal natural history of type I spinal muscular atrophy: A critical review 35
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 34
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 33
Sleep disorders in spinal muscular atrophy 32
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 31
Old measures and new scores in spinal muscular atrophy patients 31
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment 27
Long-term evolution of neuropsychological competences in encephalopathy with status epilepticus during sleep: a variable prognosis 26
An observational study of functional abilities in infants, children, and adults with type 1 SMA 26
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 25
Posterior brain damage and cognitive impairment in pediatric multiple sclerosis 25
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy 24
Neonatal hypotonia and neuromuscular conditions 23
Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions 23
Epileptic Encephalopathies with Status Epilepticus during Sleep: New Techniques for Understanding Pathophysiology and Therapeutic Options 23
Sudden and isolated Broca's aphasia: a new clinical phenotype of anti NMDA receptor antibodies encephalitis in children 21
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 21
Early neurodevelopmental assessment in Duchenne muscular dystrophy 21
The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage 21
Paediatric optic neuritis: factors leading to unfavourable outcome and relapses 21
Long term follow-up of scoliosis progression in type II SMA patients 20
Risdiplam in Type 1 Spinal Muscular Atrophy 20
New therapies for spinal muscular atrophy: where we stand and what is next 19
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 19
An observational study of functional abilities in infants, children, and adults with type 1 SMA 18
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 18
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy 18
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 17
Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis 16
Therapy of encephalopathy with status epilepticus during sleep (ESES/CSWS syndrome): an update 16
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool 15
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 14
SFP CO-31 - Inflammatory optic neuritis: Course and prognostic factors in 102 children|SFP CO-31 - Névrites optiques inflammatoires: évolution et facteurs pronostiques chez 102 enfants 14
Development of an academic disease registry for spinal muscular atrophy 12
MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients 10
How to Manage Electrical Status Epilepticus in Sleep 9
Clinical Phenotype of Pediatric and Adult Patients With Spinal Muscular Atrophy With Four SMN2 Copies: Are They Really All Stable? 8
Early treatment of type II SMA slows rate of progression of scoliosis 8
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 7
Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study 7
Profile of cognitive abilities in spinal muscular atrophy type II and III: what is the role of motor impairment? 7
Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study 6
Intravenous methylprednisolone pulse therapy for children with epileptic encephalopathy 6
Caregivers’ Expectations on Possible Functional Changes following Disease-Modifying Treatment in Type II and III Spinal Muscular Atrophy: A Comparative Study 5
Totale 3.925
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.861
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.861
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202075 0 0 1 3 5 15 16 3 1 4 23 4
2020/202170 2 6 1 3 5 7 8 1 12 5 18 2
2021/2022449 30 6 5 63 34 13 9 63 33 27 70 96
2022/20231.624 108 174 108 222 108 201 102 166 247 36 88 64
2023/20241.307 40 262 48 135 48 239 142 59 18 67 109 140
2024/2025232 49 42 141 0 0 0 0 0 0 0 0 0
Totale 3.925